irbesartan/hydrochlorothiazide actavis õhukese polümeerikattega tablett
actavis group ptc ehf. - irbesartaan+hüdroklorotiasiid - õhukese polümeerikattega tablett - 150mg+12,5mg 98tk; 150mg+12,5mg 250tk; 150mg+12,5mg 30tk; 150mg+12,5mg 60tk; 150mg+12,5mg 14tk; 150mg+12,5mg 500tk
lartokaz 300 mg/12,5 mg tablett
laboratorios liconsa s.a. - irbesartaan+hüdroklorotiasiid - tablett - 300mg+12,5mg 56tk; 300mg+12,5mg 28tk; 300mg+12,5mg 14tk
cobesar õhukese polümeerikattega tablett
actavis group ptc ehf. - irbesartaan+hüdroklorotiasiid - õhukese polümeerikattega tablett - 12,5mg+300mg 28tk
olimel peri n4e infusiooniemulsioon
baxter - kombinatsioonid - infusiooniemulsioon - 1000ml 6tk; 2000ml 4tk; 2500ml 2tk; 1500ml 4tk
olimel n9e infusiooniemulsioon
baxter - kombinatsioonid - infusiooniemulsioon - 1500ml 4tk; 2000ml 4tk; 1000ml 6tk
tobramycin via pharma nebuliseeritav lahus
via pharma uab - tobramütsiin - nebuliseeritav lahus - 300mg 5ml 56tk
cobesar õhukese polümeerikattega tablett
actavis group ptc ehf. - irbesartaan+hüdroklorotiasiid - õhukese polümeerikattega tablett - 25mg+300mg 28tk
tukysa
seagen b.v. - tucatinib - breast neoplasms; neoplasm metastasis - antineoplastilised ained - tukysa is indicated in combination with trastuzumab and capecitabine for the treatment of adult patients with her2‑positive locally advanced or metastatic breast cancer who have received at least 2 prior anti‑her2 treatment regimens.
qaialdo
nova laboratories ireland limited - spironolaktoon - edema; heart failure; liver cirrhosis; ascites; nephrotic syndrome; hyperaldosteronism; essential hypertension - antihypertensives and diuretics in combination - in the management of refractory oedema associated with congestive cardiac failure; hepatic cirrhosis with ascites and oedema, malignant ascites, nephrotic syndrome, diagnosis and treatment of primary aldosteronism, essential hypertension. neonates, children and adolescents should only be treated under guidance of a paediatric specialist (see sections 5. 1 ja 5.